<head>
<title>Core Laboratories N.V. 8K Over Allotment</title>
</head>

<html>

<body>

<b><font SIZE="2">
</font><font SIZE="4">
<p ALIGN="CENTER">UNITED STATES</p>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</p>
</font><font SIZE="2">
<p ALIGN="CENTER">Washington, D.C. 20549</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">________________</p>
</font><b><font SIZE="5">
<p ALIGN="CENTER">FORM 8-K</p>
</font></b>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="684">
  <tr>
    <td VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="TOP"><font SIZE="2">
      <p>CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934</font></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
    <p align="center">
<FONT SIZE=2>Date of report (Date of earliest event reported):<B> November 20, 2006 (November 15, 2006)</B></FONT></td>
  </tr>
  <tr>
    <td VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<p>&nbsp;</p>
</font><b><font FACE="Times" SIZE="5">
<p ALIGN="CENTER">CORE LABORATORIES N.V.</p>
</font></b><font SIZE="2">
<p ALIGN="CENTER">(Exact name of registrant as specified in its charter)</p>
<p ALIGN="CENTER"><b>001-14273<br>
</b>(Commission File Number)</p>
</font>
<p ALIGN="CENTER"><center>
<div align="center">
  <center>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680">
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(State or other jurisdiction of incorporation or
      organization)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(I.R.S. Employer Identification No.)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Herengracht 424</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">1017 BZ Amsterdam</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">The Netherlands</font></b></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><b><font SIZE="2">
      <p ALIGN="CENTER">Not Applicable</font></b></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Address of principal executive offices)</font></td>
    <td WIDTH="49%" VALIGN="MIDDLE"><font SIZE="2">
      <p ALIGN="CENTER">(Zip Code)</font></td>
  </tr>
  <tr>
    <td WIDTH="51%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="49%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
</table>
  </center>
</div>
</center><font SIZE="2">
<p ALIGN="CENTER">Registrant's telephone number, including area code: <b>(31-20)
420-3191</b></p>
<p ALIGN="CENTER">&nbsp;</p>
<p ALIGN="left"><font SIZE="2">Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </font></p>
<table CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="680" style="border-left-width: 0; border-top-width: 0; border-bottom-width: 0">
  <tr>
    <td WIDTH="44" style="border-style: none; border-width: medium">
    <p align="center">___</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Written communications
    pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <font SIZE="2">
      <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Soliciting material
      pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      <p class="MsoNormal"><font SIZE="2">Pre-commencement
      communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">&nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium"><font SIZE="2">
    <p align="center">___</font></td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
    <p class="MsoNormal"><font SIZE="2">Pre-commencement
    communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))</font></td>
  </tr>
  <tr>
    <td WIDTH="44" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      &nbsp;</td>
    <td WIDTH="636" VALIGN="MIDDLE" style="border-left-style: none; border-left-width: medium">
      &nbsp;</td>
  </tr>
</table>
<hr>
<B><P>Item 1.01.  Entry into a Material Definitive Agreement.</P>
</B><P>On November 17, 2006, the Initial Purchasers (as defined herein)
purchased an additional $50,000,000 of the 0.25% Senior Exchangeable Notes Due
2011 (the &quot;Additional Notes&quot;) of Core Laboratories LP (&quot;Core LP&quot;), pursuant to
the Purchase Agreement, dated November 6, 2006, among Core Laboratories N.V.
(&quot;Core NV&quot;), Core LP and Lehman Brothers Inc. and Banc of America Securities
LLC, as representatives of the initial purchasers named therein (the &quot;Initial
Purchasers&quot;). The Additional Notes increase the aggregate issuance by Core LP of
0.25% Senior Exchangeable Notes Due 2011 to $300,000,000. The Additional Notes
are exchangeable under certain conditions for Core NV's common shares as
previously disclosed. The net proceeds from the offering of the Additional
Notes, after deducting the Initial Purchasers' discount and the estimated
offering expenses payable by Core NV, are expected to be approximately $49.0 million.</P>
<P>In connection with the issuance of the Additional Notes, Core LP amended the exchangeable note hedge transactions entered into with Lehman Brothers OTC Derivatives Inc. (the "Dealer") at the initial closing with respect to Core NV's common shares to cover the additional net Core NV's common shares that could be deliverable to exchanging noteholders
in the event of an exchange of the Additional Notes. Core LP paid the Dealer an
additional amount of approximately $14.4 million in connection with the amendment to the note hedge transactions.  A copy of the amendment to the Note Hedge Confirmation is attached hereto as Exhibit&nbsp;4.1, is incorporated herein by reference, and is hereby filed; the description of the amendment to the Note Hedge Confirmation in this report is a summary and is qualified in its entirety by the terms of the amendment.</P>
<P>Core NV also entered into an amendment of its separate warrant transactions
entered into with the Dealer at the initial closing under the Purchase Agreement
to increase the number of warrants sold to acquire Core NV's common shares. Core
NV received from the Dealer an additional amount of approximately $8.4 million in connection with the amendment to the warrant transactions.  A copy of the amendment to the Warrant Confirmation is attached hereto as Exhibit&nbsp;4.2, is incorporated herein by reference, and is hereby filed; the description of the amendment to the Warrant Confirmation in this report is a summary and is qualified in its entirety by the terms of the amendment.</P>
<B><P>Item 2.03.  Creation of a Direct Financial Obligation or an Obligation under an Off&#8722;Balance Sheet Arrangement of a Registrant.</P>
</B><P>See Item 1.01.</P>
<B><P>Item 3.02.  Unregistered Sales of Equity Securities.</P>
</B><P>See Item 1.01.</P>
<B><P>Item 9.01.  Financial Statements and Exhibits.</P>
</B>
<FONT FACE="Arial" SIZE=3>
<font SIZE="2" FACE="Times New Roman">
<font SIZE="2">
<b>
<table class="MsoNormalTable" style="width: 468.75pt" cellSpacing="0" cellPadding="0" width="625" border="0">
  <tr>
    <td style="width: 4%; padding: 0in" width="4%">&nbsp;</td>
    <td style="width: 4%; padding: 0in" width="4%">
    <p style="text-align: center" align="right"><font SIZE="2">(d)</font></td>
    <td style="width: 1%; padding: 0in" width="1%">&nbsp;</td>
    <td style="width: 91%; padding: 0in" width="91%"><i>
    <font SIZE="2">Exhibits</font></i></td>
  </tr>
</table>
</b>
</font>
<P ALIGN="JUSTIFY">&nbsp;</P>
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0" style="border-left-width: 0; border-right-width: 0">
  <tr>
    <font SIZE="2">
    <td WIDTH="22%" VALIGN="TOP">
      <p align="center"><font size="2">4.1</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
      <p>
<FONT SIZE=2>Amendment to Note Hedge Confirmation, dated November 15, 2006, Lehman Brothers OTC Derivatives Inc. and Core Laboratories L.P.</FONT></td>
</font>

  </tr>
  <tr>
    <font SIZE="2">
    <td WIDTH="22%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
      &nbsp;</td>
</font>

  </tr>
  <tr>
    <font SIZE="2">
    <td WIDTH="22%" VALIGN="TOP">
    <p align="center"><font size="2">4.2</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
<FONT SIZE=2>Amendment to Warrant Confirmation, dated November 15, 2006, between Lehman Brothers OTC Derivatives Inc. and Core Laboratories N.V.</FONT></td>
</font>

  </tr>
</table>
</font>
<font SIZE="2" FACE="Arial">
</font>
</FONT>

<b>
<p></p>
<hr>
<p ALIGN="CENTER">SIGNATURES</b></p>
<p>Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>
<center>
<div align="right">
<table BORDER="0" CELLSPACING="0" WIDTH="635" cellpadding="0">
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="48%" VALIGN="bottom" COLSPAN="5"><font SIZE="2">
      <p>Core Laboratories N.V.</font></td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom"><font SIZE="2">
      <p>Dated: November 20, 2006</font></td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom"><font SIZE="2">
      <p>By</font></td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p style="border-bottom-style: solid; border-bottom-width: 1">/s/ Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p>Richard L. Bergmark</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="47%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="5%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="1%" VALIGN="bottom">
      <p>&nbsp;</td>
    <td WIDTH="40%" VALIGN="bottom"><font SIZE="2">
      <p>Chief Financial Officer</font></td>
    <td WIDTH="1%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="TOP">
      <p>&nbsp;</td>
  </tr>
</table>
</div>
</center><font SIZE="2">
<p>&nbsp;</p>
<hr>
<b>
<p ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</b></p>
<b>
<p ALIGN="CENTER">CORE LABORATORIES N.V.<br>
EXHIBIT INDEX TO FORM 8-K</b></p>
<p ALIGN="left">&nbsp;</p>
<p ALIGN="left">&nbsp;</p>
<center>
<div align="left">
<table CELLSPACING="0" BORDER="0" WIDTH="570" cellpadding="0" style="border-left-width: 0; border-right-width: 0">
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE" style="border-bottom-style: none; border-bottom-width: medium">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE" style="border-bottom-style: none; border-bottom-width: medium">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE" style="border-bottom-style: none; border-bottom-width: medium">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
    <div style="border-bottom-style: solid; border-bottom-width: 1">
      <b><font SIZE="2">
      EXHIBIT NO.</font></b></div>
    </td>
    <td WIDTH="3%" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE" style="border-style: none; border-width: medium">
    <div style="border-bottom-style: solid; border-bottom-width: 1">
      <b><font SIZE="2">
      ITEM</font></b></div>
    </td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="MIDDLE" style="border-top-style: none; border-top-width: medium">
      <p>&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE" style="border-top-style: none; border-top-width: medium">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="MIDDLE" style="border-top-style: none; border-top-width: medium">
      <p>&nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP">
      <p align="center"><font size="2">4.1</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      <p>&nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
      <p>
<FONT SIZE=2>Amendment to Note Hedge Confirmation, dated November 15, 2006, Lehman Brothers OTC Derivatives Inc. and Core Laboratories L.P.</FONT></td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP">&nbsp;</td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
      &nbsp;</td>
  </tr>
  <tr>
    <td WIDTH="22%" VALIGN="TOP">
    <p align="center"><font size="2">4.2</font></td>
    <td WIDTH="3%" VALIGN="MIDDLE">
      &nbsp;</td>
    <td WIDTH="75%" VALIGN="TOP">
<FONT SIZE=2>Amendment to Warrant Confirmation, dated November 15, 2006, between Lehman Brothers OTC Derivatives Inc. and Core Laboratories N.V.</FONT></td>
  </tr>
</table>
</div>
</center>
<p>&nbsp;</p>
<p>&nbsp;</p>
</font>

</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "clb-8k_overallotamendments.htm", "description": "8-K", "secsgml_size_bytes": 16490}]
{"company-data": {"conformed-name": "CORE LABORATORIES N V", "cik": "0001000229", "assigned-sic": "1389", "irs-number": "000000000", "state-of-incorporation": "P7", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14273", "film-number": "061230525"}, "business-address": {"street1": "1017 BZ AMSTERDAM", "street2": "HERENGRACHT 424", "city": "THE NETHERLANDS", "state": "P7", "phone": "3124203191"}, "mail-address": {"street1": "6316 WINDFERN", "city": "HOUSTON", "state": "TX", "zip": "77040"}}
Core Laboratories N.V. 8K Over Allotment
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
      EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
November 20, 2006 (November 15, 2006)
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
001-14273
(Commission File Number)
The Netherlands
Not Applicable
(State or other jurisdiction of incorporation or
      organization)
(I.R.S. Employer Identification No.)
Herengracht 424
1017 BZ Amsterdam
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
___
Soliciting material
      pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
___
Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2 (b))
___
Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
    240.13e-4 (c))
Item 1.01.  Entry into a Material Definitive Agreement.
On November 17, 2006, the Initial Purchasers (as defined herein)
purchased an additional $50,000,000 of the 0.25% Senior Exchangeable Notes Due
2011 (the "Additional Notes") of Core Laboratories LP ("Core LP"), pursuant to
the Purchase Agreement, dated November 6, 2006, among Core Laboratories N.V.
("Core NV"), Core LP and Lehman Brothers Inc. and Banc of America Securities
LLC, as representatives of the initial purchasers named therein (the "Initial
Purchasers"). The Additional Notes increase the aggregate issuance by Core LP of
0.25% Senior Exchangeable Notes Due 2011 to $300,000,000. The Additional Notes
are exchangeable under certain conditions for Core NV's common shares as
previously disclosed. The net proceeds from the offering of the Additional
Notes, after deducting the Initial Purchasers' discount and the estimated
offering expenses payable by Core NV, are expected to be approximately $49.0 million.
In connection with the issuance of the Additional Notes, Core LP amended the exchangeable note hedge transactions entered into with Lehman Brothers OTC Derivatives Inc. (the "Dealer") at the initial closing with respect to Core NV's common shares to cover the additional net Core NV's common shares that could be deliverable to exchanging noteholders
in the event of an exchange of the Additional Notes. Core LP paid the Dealer an
additional amount of approximately $14.4 million in connection with the amendment to the note hedge transactions.  A copy of the amendment to the Note Hedge Confirmation is attached hereto as Exhibit 4.1, is incorporated herein by reference, and is hereby filed; the description of the amendment to the Note Hedge Confirmation in this report is a summary and is qualified in its entirety by the terms of the amendment.
Core NV also entered into an amendment of its separate warrant transactions
entered into with the Dealer at the initial closing under the Purchase Agreement
to increase the number of warrants sold to acquire Core NV's common shares. Core
NV received from the Dealer an additional amount of approximately $8.4 million in connection with the amendment to the warrant transactions.  A copy of the amendment to the Warrant Confirmation is attached hereto as Exhibit 4.2, is incorporated herein by reference, and is hereby filed; the description of the amendment to the Warrant Confirmation in this report is a summary and is qualified in its entirety by the terms of the amendment.
Item 2.03.  Creation of a Direct Financial Obligation or an Obligation under an Off−Balance Sheet Arrangement of a Registrant.
See Item 1.01.
Item 3.02.  Unregistered Sales of Equity Securities.
See Item 1.01.
Item 9.01.  Financial Statements and Exhibits.
(d)
Exhibits
4.1
Amendment to Note Hedge Confirmation, dated November 15, 2006, Lehman Brothers OTC Derivatives Inc. and Core Laboratories L.P.
4.2
Amendment to Warrant Confirmation, dated November 15, 2006, between Lehman Brothers OTC Derivatives Inc. and Core Laboratories N.V.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Core Laboratories N.V.
Dated: November 20, 2006
By
/s/ Richard L. Bergmark
Richard L. Bergmark
Chief Financial Officer
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
EXHIBIT NO.
ITEM
4.1
Amendment to Note Hedge Confirmation, dated November 15, 2006, Lehman Brothers OTC Derivatives Inc. and Core Laboratories L.P.
4.2
Amendment to Warrant Confirmation, dated November 15, 2006, between Lehman Brothers OTC Derivatives Inc. and Core Laboratories N.V.